Arun Swaminath, MD
Gastroenterology · New York, NYNPI 1730289398
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Pfizer at 31.3% of the total. 2025 is the largest year on record at $12,483, 3.8 times the $3,265 reported in 2019.
Across 55 payments — averaging $355.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Sanofi US Services Inc.$3K
- Boehringer Ingelheim$3K
- Mirum Pharmaceuticals, Inc.$3K
- Gilead$2K
- Olympus Corporation Of The Americas$601
- plus $906 from 8 others
Across 631 payments — averaging $4321.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$961K
- Takeda Pharmaceuticals U.S.A., Inc.$678K
- Bristol Myers Squibb$454K
- Janssen Research & Development, LLC$307K
- Gilead$171K
- Roche Products Limited$82K
- plus $74K from 3 others
What the payments were for
- Consulting fees$11,60859%
- Speaking & faculty fees$5,69029%
- Travel & lodging$1,1326%
- Food & beverage$9995%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $6,111 |
| Sanofi US Services Inc. | 1 | $3,428 |
| Boehringer Ingelheim | 1 | $3,250 |
| Mirum Pharmaceuticals, Inc. | 2 | $2,977 |
| Gilead | 6 | $2,256 |
| Olympus Corporation Of The Americas | 6 | $601 |
| Johnson & Johnson | 14 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $199 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| AbbVie | 3 | $93 |
| Procyrion, Inc. | 1 | $33 |
| Shire North American Group Inc | 1 | $25 |
| Merck | 1 | $24 |
| Olympus America Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VELSIPITY$5,828
- AYVAKIT$3,428
- EVIS EXERA$572
- Olympus Capital Accessories$572
- ScopeGuide$572
- ZEPOSIA$125
- Entyvio$125
How this compares
$19,529 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.